AAAAAA
Results:
1-23
|
Results: 23
Authors:
Melchior, SW
Noteboom, J
Gillitzer, R
Lange, PH
Blumenstein, BA
Vessella, RL
Citation: Sw. Melchior et al., The percentage of free prostate-specific antigen does not predict extracapsular disease in patients with clinically localized prostate cancer before radical prostatectomy, BJU INT, 88(3), 2001, pp. 221-225
Authors:
Brown, JM
Vessella, RL
Kostenuik, PJ
Dunstan, CR
Lange, PH
Corey, E
Citation: Jm. Brown et al., Serum osteoprotegerin levels are increased in patients with advanced prostate cancer, CLIN CANC R, 7(10), 2001, pp. 2977-2983
Authors:
Hass, GM
Meyer, JL
Newitt, RA
Labuda, T
Brown, L
Aebersold, R
Vessella, RL
Citation: Gm. Hass et al., Identification of the target of monoclonal antibody A6H as dipeptidyl peptidase IV/CD26 by LC MS backslash MS, HYBRIDOMA, 20(4), 2001, pp. 231-236
Authors:
Brown, JM
Corey, E
Lee, ZD
True, LD
Yun, TJ
Tondravi, M
Vessella, RL
Citation: Jm. Brown et al., Osteoprotegerin and rank ligand expression in prostate cancer, UROLOGY, 57(4), 2001, pp. 611-616
Authors:
Ellis, WJ
Etzioni, R
Vessella, RL
Hu, CC
Goodman, GE
Citation: Wj. Ellis et al., Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostatecancer, J UROL, 166(1), 2001, pp. 93-98
Authors:
Thomas, R
True, LD
Lange, PH
Vessella, RL
Citation: R. Thomas et al., Placental bone morphogenetic protein (PLAB) gene expression in normal, pre-malignant and malignant human prostate: Relation to tumor development and progression, INT J CANC, 93(1), 2001, pp. 47-52
Authors:
Wang, SY
Diamond, DL
Hass, GM
Sokoloff, R
Vessella, RL
Citation: Sy. Wang et al., Identification of prostate specific membrane antigen (PSMA) as the target of monoclonal antibody 107-1A4 by proteinchip (R); Array, surface-enhanced laser desorption/ionization (SELDI) technology, INT J CANC, 92(6), 2001, pp. 871-876
Authors:
Linja, MJ
Savinainen, KJ
Saramaki, OR
Tammela, TLJ
Vessella, RL
Visakorpi, T
Citation: Mj. Linja et al., Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer, CANCER RES, 61(9), 2001, pp. 3550-3555
Authors:
Vessella, RL
Wilbur, DS
Buhler, K
Lange, PH
Citation: Rl. Vessella et al., Experimental models and methods in antibody targeting of renal cell carcinoma, METH MOL M, 53, 2001, pp. 217-242
Authors:
Thomas, R
True, LD
Bassuk, JA
Lange, PH
Vessella, RL
Citation: R. Thomas et al., Differential expression of osteonectin/SPARC during human prostate cancer progression, CLIN CANC R, 6(3), 2000, pp. 1140-1149
Authors:
Buhler, KR
Santucci, RA
Royal, RA
Whitney, SC
Vessella, RL
Lange, PH
Ellis, WJ
Citation: Kr. Buhler et al., Intermittent androgen suppression in the LuCaP 23.12 prostate cancer xenograft model, PROSTATE, 43(1), 2000, pp. 63-70
Authors:
Vessella, RL
Lange, PH
Partin, AW
Chan, DW
Sokoll, LJ
Sasse, EA
Crawford, ED
Citation: Rl. Vessella et al., Probability of prostate cancer detection based on results of a multicenterstudy using the AxSYM free PSA and total PSA assays, UROLOGY, 55(6), 2000, pp. 909-914
Authors:
Graff, JR
Konicek, BW
McNulty, AM
Wang, ZJ
Houck, K
Allen, S
Paul, JD
Hbaiu, A
Goode, RG
Sandusky, GE
Vessella, RL
Neubauer, BL
Citation: Jr. Graff et al., Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27(Kip1) expression, J BIOL CHEM, 275(32), 2000, pp. 24500-24505
Authors:
Corey, MJ
Kinders, RJ
Poduje, CM
Bruce, CL
Rowley, H
Brown, LG
Hass, GM
Vessella, RL
Citation: Mj. Corey et al., Mechanistic studies of the effects of anti-factor H antibodies on complement-mediated lysis, J BIOL CHEM, 275(17), 2000, pp. 12917-12925
Authors:
Wilbur, DS
Pathare, PM
Hamlin, DK
Stayton, PS
To, R
Klumb, LA
Buhler, KR
Vessella, RL
Citation: Ds. Wilbur et al., Development of new biotin/streptavidin reagents for pretargeting, BIOMOL ENG, 16(1-4), 1999, pp. 113-118
Authors:
Goedert, JJ
Sauter, ME
Jacobson, LP
Vessella, RL
Hilgartner, MW
Leitman, SF
Fraser, MC
Mueller-Lantzsch, NG
Citation: Jj. Goedert et al., High prevalence of antibodies against HERV-K10 in patients with testicularcancer but not with AIDS, CANC EPID B, 8(4), 1999, pp. 293-296
Authors:
Melchior, SW
Brown, LG
Figg, WD
Quinn, JE
Santucci, RA
Brunner, J
Thuroff, JW
Lange, PH
Vessella, RL
Citation: Sw. Melchior et al., Effects of phenylbutyrate on proliferation and apoptosis in human prostatecancer cells in vitro and in vivo, INT J ONCOL, 14(3), 1999, pp. 501-508
Authors:
Vessella, RL
Citation: Rl. Vessella, Molecular staging of prostate cancer: Dream or reality? The de la Taille/Olsson/Katz article reviewed, ONCOLOGY-NY, 13(2), 1999, pp. 194
Authors:
Liu, AY
True, LD
LaTray, L
Ellis, WJ
Vessella, RL
Lange, PH
Higano, CS
Hood, L
van den Engh, G
Citation: Ay. Liu et al., Analysis and sorting of prostate cancer cell types by flow cytometry, PROSTATE, 40(3), 1999, pp. 192-199
Authors:
Veltri, RW
Miller, MC
Zhao, G
Ng, A
Marley, GM
Wright, GL
Vessella, RL
Ralph, D
Citation: Rw. Veltri et al., Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer, UROLOGY, 53(1), 1999, pp. 139-147
Authors:
Lange, PH
Vessella, RL
Citation: Ph. Lange et Rl. Vessella, Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction - Comment, J UROL, 161(4), 1999, pp. 1076-1076
Authors:
Ellis, WJ
Vessella, RL
Corey, E
Arfman, EW
Oswin, MM
Melchoir, S
Lange, PH
Citation: Wj. Ellis et al., The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer - Reply, J UROL, 161(3), 1999, pp. 925-926
Authors:
Lange, PH
Vessella, RL
Citation: Ph. Lange et Rl. Vessella, Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone, CANC METAST, 17(4), 1998, pp. 331-336
Risultati:
1-23
|